A10241 | Pages: NA | Jul 2022 | 377 Views | | |
Author(s) : NA | Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Allergy Immunotherapy Market
Request Now !Allergy immunotherapy is an adaptive therapy for diseases which is effectual during the treatment of allergic conjunctivitis, peanuts allergy, allergic asthma, cat allergy, stinging insect hypersensitivity, etc.. Immunotherapy is a treatment for prevention of various allergic reactions like house dust mites, grass pollens, and bee venom. Immunotherapy is increasing the dosages of the substance in which the person is allergic over some time. Increase in the allergens causes the immune system to lower the sensitivity to the substance by causing the production of an antibody that will reduce the symptoms of allergy when the person comes in contact with the substance in the future. Immunotherapy is also used to reduce the inflammation of diseases like rhinitis and asthma.
Before initiating the treatment, the immunology physician and patient identify all the trigger factors for allergy symptoms. Various skin and blood tests are performed for the confirmation of specific antigens to which the person has antibodies. Immunotherapy is usually commended only and only if the person seems to be selectively sensitive to several allergens.
Market scope and structure analysis:
Report Metric | Details |
Market size available for years | 2019–2027 |
Base year considered | 2019 |
Forecast period | 2020–2027 |
Forecast units | Value (USD) |
Segments covered | Allergy Type, Treatment, Distribution Channel and Region |
Geographies covered | North America (US and Canada), Europe (Germany, UK, France, and the Rest of Europe), Asia Pacific (China, Japan, India, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of LATAM) and The Middle East and Africa |
Companies covered | Major players analyzed include ALK Abello A/S, Allergy Therapeutic, Circassia, DBV Technologies, Stallergenes Greer, Merck KGaA (Allergopharma), WOLWpharma, HolisterStier, Letiand HAL Allergy Group. |
COVID-19 scenario analysis:
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
Owing to such factors, COVID 19 is expected to have a significant impact on the Allergy immunotherapy market.
After the launches of various new sublingual immuno-therapies in developing countries and the influence of many major players in the allergen immunotherapy market, an increase in an unmet need for novel targeted drugs which can be used to treat the disease conditions are the major factors driving the market. Sublingual allergy immunotherapy has now been clinically proven a more efficient treatment with lesser side effects as compared to alternatives available in the market currently. There is also a change observed in demographics concerning population and macroeconomic climate are other factors driving towards allergy immunotherapy market.
On the other hand, allergy immunotherapy drugs can also cause severe allergic reactions that may be fatal in some cases, and due to the limited availability of therapy in few countries it is a challenge for the allergy immunotherapy market. Additionally, less awareness about immunotherapy is limiting the growth of the sublingual allergy immunotherapy market. Also there is a lack of skilled professionals and high technological cost which is hampering the market’s development.
In January 2017, ALK Abello A/S acquired of Allergy Laboratory of Oklahoma Inc. and Crystal Labs LLC.
In October 2017, DBV Technologies entered intoR and D agreement with Stallergenes S.A. for birch allergy treatment.
In January 2017, Merck acquired BioControl which helped them strengthen their capabilities in food safety testing.
Improving and significantly growing healthcare infrastructure, and growing awareness about allergy immunotherapy and there is also a high prevalence of nasal allergies been observed in the recent year which will increase the demand for allergy treatment market.
Key segments covered:
Segments | Sub-segments |
Allergy Type |
|
Treatment |
|
Distribution Channel |
|
Regions |
|
Key benefits of the report:
Questions answered in the Allergy immunotherapy Market research report:
Key Market Segments
Segments | Sub-segments |
---|---|
By Allergy Type |
|
By Treatment |
|
By Distribution Channel |
|
By Region |
|
Key Market Players
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers